BC-box protein domain-related mechanism for VHL protein degradation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 45, 2013, Pages 18168-18173

  Pozzebon, Maria Elena ^a,d   Varadaraj, Archana ^a   Mattoscio, Domenico ^a   Jaffray, Ellis G ^b   Miccolo, Claudia ^a   Galimberti, Viviana ^a   Tommasino, Massimo ^c   Hay, Ronald T ^b   Chiocca, Susanna ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d TREVISO REGIONAL HOSPITAL   (Italy)

Author keywords

Hypoxia; Oncoviral proteins; Ubiquitylation

Indexed keywords

BC BOX PROTEIN; CELL PROTEIN; CULLIN; CULLIN2 PROTEIN; CULLIN5 PROTEIN; GAM1 PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEASOME; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VIRUS PROTEIN; VON HIPPEL LINDAU PROTEIN;

ADENOVIRUS 5; ADENOVIRUS INFECTION; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; HEAT SHOCK; HELA CELL; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; INTRACELLULAR SIGNALING; KERATINOCYTE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN STABILITY; REGULATORY MECHANISM; UBIQUITINATION; VIRUS CARCINOGENESIS; VIRUS REACTIVATION; VIRUS REPLICATION;

HYPOXIA; ONCOVIRAL PROTEINS; UBIQUITYLATION;

CELL LINE, TUMOR; CULLIN PROTEINS; DNA PRIMERS; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LUCIFERASES; PROTEIN STRUCTURE, TERTIARY; PROTEOLYSIS; REAL-TIME POLYMERASE CHAIN REACTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TRANSCRIPTION FACTORS; UBIQUITIN-PROTEIN LIGASE COMPLEXES; VIRAL PROTEINS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84887298778     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1311382110     Document Type: Article

References (55)

1. Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67: 425-479.
2. Petroski MD, Deshaies RJ (2005) Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 6(1):9-20.
3. Yan Q, et al. (2004) Identification of Elongin C and Skp1 sequences that determine Cullin selection. J Biol Chem 279(41):43019-43026.
4. Duan DR, et al. (1995) Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269(5229):1402-1406.
5. Kamura T, et al. (1998) The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev 12(24):3872-3881.
6. Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG, Jr. (1995) Binding of the von Hippel- Lindau tumor suppressor protein to Elongin B and C. Science 269(5229):1444-1446.
7. Kamura T, et al. (2004) VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. Genes Dev 18(24):3055-3065.
8. Zhang JG, et al. (1999) The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc Natl Acad Sci USA 96(5):2071-2076.
9. Hilton DJ, et al. (1998) Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci USA 95(1):114-119.
10. Blanchette P, et al. (2004) Both BC-box motifs of adenovirus protein E4orf6 are required to efficiently assemble an E3 ligase complex that degrades p53. Mol Cell Biol 24(21):9619-9629.
11. Cai QL, Knight JS, Verma SC, Zald P, Robertson ES (2006) EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors. PLoS Pathog 2(10):e116.
12. Cheng CY, Blanchette P, Branton PE (2007) The adenovirus E4orf6 E3 ubiquitin ligase complex assembles in a novel fashion. Virology 364(1):36-44.
13. Huh K, et al. (2007) Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor. J Virol 81(18):9737-9747.
14. Luo K, et al. (2007) Adenovirus E4orf6 assembles with Cullin5-ElonginB-ElonginC E3 ubiquitin ligase through an HIV/SIV Vif-like BC-box to regulate p53. FASEB J 21(8): 1742-1750.
15. Querido E, et al. (2001) Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev 15(23):3104-3117.
16. Yu X, et al. (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV- 1 Vif-Cul5-SCF complex. Science 302(5647):1056-1060.
17. Yu Y, Xiao Z, Ehrlich ES, Yu X, Yu XF (2004) Selective assembly of HIV-1 Vif-Cul5- ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev 18(23):2867-2872.
18. Boggio R, Colombo R, Hay RT, Draetta GF, Chiocca S (2004) A mechanism for inhibiting the SUMO pathway. Mol Cell 16(4):549-561.
19. Boggio R, Passafaro A, Chiocca S (2007) Targeting SUMO E1 to ubiquitin ligases: A viral strategy to counteract sumoylation. J Biol Chem 282(21):15376-15382.
20. Chiocca S, et al. (2002) Histone deacetylase 1 inactivation by an adenovirus early gene product. Curr Biol 12(7):594-598.
21. Colombo R, Boggio R, Seiser C, Draetta GF, Chiocca S (2002) The adenovirus protein Gam1 interferes with sumoylation of histone deacetylase 1. EMBO Rep 3(11):1062-1068.
22. Lisztwan J, Imbert G, Wirbelauer C, Gstaiger M, Krek W (1999) The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev 13(14):1822-1833.
23. Ohh M, et al. (1999) Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein. J Clin Invest 104(11):1583-1591.
24. Pause A, et al. (1997) The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci USA 94(6):2156-2161.
25. Chen F, et al. (1995) Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: Correlations with phenotype. Hum Mutat 5(1):66-75.
26. Latif F, et al. (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260(5112):1317-1320.
27. Ivan M, et al. (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science 292(5516):464-468.
28. Jaakkola P, et al. (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292(5516):468-472.
29. Maxwell PH, et al. (1999) The tumour suppressor protein VHL targets hypoxiainducible factors for oxygen-dependent proteolysis. Nature 399(6733):271-275.
30. Ohh M, et al. (2000) Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2(7):423-427.
31. Forsythe JA, et al. (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16(9):4604-4613.
32. Wang GL, Semenza GL (1993) General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 90(9):4304-4308.
33. Zelzer E, et al. (1998) Insulin induces transcription of target genes through the hypoxia- inducible factor HIF-1alpha/ARNT. EMBO J 17(17):5085-5094.
34. Glotzer JB, et al. (2000) Activation of heat-shock response by an adenovirus is essential for virus replication. Nature 407(6801):207-211.
35. Loncaster JA, et al. (2001) Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: Correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61(17):6394-6399.
36. Chou MT, Anthony J, Bjorge JD, Fujita DJ (2010) The von Hippel-Lindau tumor suppressor protein is destabilized by Src: Implications for tumor angiogenesis and progression. Genes Cancer 1(3):225-238.
37. Babon JJ, Sabo JK, Zhang JG, Nicola NA, Norton RS (2009) The SOCS box encodes a hierarchy of affinities for Cullin5: Implications for ubiquitin ligase formation and cytokine signalling suppression. J Mol Biol 387(1):162-174.
38. Schoenfeld AR, Davidowitz EJ, Burk RD (2000) Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products. Proc Natl Acad Sci USA 97(15):8507-8512.
39. Chen YJ, et al. (2010) Heat shock protein 72 is associated with the hepatitis C virus replicase complex and enhances viral RNA replication. J Biol Chem285(36):28183-28190.
40. Gonzalez O, et al. (2009) The heat shock protein inhibitor Quercetin attenuates hepatitis C virus production. Hepatology 50(6):1756-1764.
41. Punjabi AS, Carroll PA, Chen L, Lagunoff M (2007) Persistent activation of STAT3 by latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells. J Virol 81(5):2449-2458.
42. Ho HH, Ivashkiv LB (2006) Role of STAT3 in type I interferon responses: Negative regulation of STAT1-dependent inflammatory gene activation. J Biol Chem 281(20):14111-14118.
43. Tanabe Y, et al. (2005) Cutting edge: Role of STAT1, STAT3, and STAT5 in IFN-alpha beta responses in T lymphocytes. J Immunol 174(2):609-613.
44. Ginsberg HS, et al. (1989) Role of early region 3 (E3) in pathogenesis of adenovirus disease. Proc Natl Acad Sci USA 86(10):3823-3827.
45. Münger K, Scheffner M, Huibregtse JM, Howley PM (1992) Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. Cancer Surv 12:197-217.
46. Pugh CW, Ratcliffe PJ (2003) Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat Med 9(6):677-684.
47. Liao D, Corle C, Seagroves TN, Johnson RS (2007) Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 67(2):563-572.
48. Cai Q, Robertson ES (2010) Ubiquitin/SUMO modification regulates VHL protein stability and nucleocytoplasmic localization. PLoS ONE 5(9):e12636.
49. Hwang II, Watson IR, Der SD, Ohh M (2006) Loss of VHL confers hypoxia-inducible factor (HIF)-dependent resistance to vesicular stomatitis virus: Role of HIF in antiviral response. J Virol 80(21):10712-10723.
50. Naldini A, Carraro F, Fleischmann WR, Jr., Bocci V (1993) Hypoxia enhances the antiviral activity of interferons. J Interferon Res 13(2):127-132.
51. NasimuzzamanM, Waris G, Mikolon D, Stupack DG, Siddiqui A (2007) Hepatitis C virus stabilizes hypoxia-inducible factor 1alpha and stimulates the synthesis of vascular endothelial growth factor. J Virol 81(19):10249-10257.
52. Moon EJ, et al. (2004) Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-inducible factor-1alpha. FASEB J 18(2):382-384.
53. Tang X, et al. (2007) Overexpression of human papillomavirus type 16 oncoproteins enhances hypoxia-inducible factor 1 alpha protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells. Clin Cancer Res 13(9):2568-2576.
54. Wakisaka N, et al. (2004) Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1 alpha. Mol Cell Biol 24(12):5223-5234.
55. Zhao WT, et al. (2013) The von Hippel-Lindau protein pVHL inhibits ribosome biogenesis and protein synthesis. J Biol Chem 288(23):16588-16597.